Table 3.
Comparison of outcomes between E+P MHT and unexposed participants
| Outcome | No. of participants (annualized %) | Unadjusted HR (95% CI) |
Adjusted HR (95% CI)* |
|
|---|---|---|---|---|
| E+P MHT (n=4,712) |
E+P unexposed (n=8,070) |
|||
| Follow-up time in months mean (range) | 111.8 (5.6–126.9) | 110.2 (0.4–127.0) | NA | NA |
| Acute MI | 32 (0.07) | 69 (0.09) | 0.78 (0.51–1.19) | 0.76 (0.50–1.16) |
| CHD Death | 10 (0.02) | 14 (0.02) | 1.21 (0.53–2.70) | 1.16 (0.51–2.64) |
| Breast cancer | 160 (0.36) | 183 (0.24) | 1.48 (1.20–1.83) | 1.44 (1.16–1.79) |
| Stroke | 184 (0.41) | 493 (0.65) | 0.62 (0.53–0.74) | 0.62 (0.53–0.74) |
| CABG/PTCA | 58 (0.13) | 50 (0.06) | 1.95 (1.34–2.85) | 1.82 (1.25–2.68) |
| PE | 9 (0.02) | 16 (0.02) | 0.95 (0.42–2.14) | 0.80 (0.35–1.85) |
| DVT | 18 (0.04) | 35 (0.05) | 0.87 (0.49–1.53) | 0.90 (0.51–1.60) |
| Colon cancer | 23 (0.05) | 67 (0.09) | 0.58 (0.36–0.93) | 0.62 (0.39–1.00) |
| Endometrial | 38 (0.09) | 30 (0.04) | 2.15 (1.33–3.47) | 2.22 (1.37–3.61) |
| Any cancer | 806 (1.81) | 1112 (1.46) | 1.26 (1.15–1.38) | 1.29 (1.18–1.42) |
| Vertebral and hip fractures | 111 (0.26) | 251 (0.34) | 0.74 (0.59–0.93) | 0.80 (0.64–1.0) |
| Any fracture | 304 (0.71) | 604 (0.84) | 0.82 (0.72–0.95) | 0.89 (0.78–1.03) |
| Death | 161 (0.36) | 505 (0.66) | 0.54 (0.45–0.64) | 0.56 (0.47–0.67) |
| Global index | 626 (1.50) | 1324 (1.89) | 0.79 (0.72–0.87) | 0.81 (0.74–0.90) |
*
Adjusted for age, statin use, aspirin use, hypercholesterolemia, diabetes medication use, hypertension